

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 24, 2004

SIGA Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware

0-23047

13-3864870

(State or other Jurisdiction of
Incorporation or Organization)

(Commission File
Number)

(I.R.S. Employer
Identification Number)

420 Lexington Avenue, Suite 601, New York, New York

10170

(Address of Principal Executive Offices)

(Zip Code)

(212) 672-9100

(Registrant's telephone number, including area code)

ITEM 7.01. Regulation FD Disclosure.

On November 24, 2004, SIGA Technologies, Inc., a Delaware corporation, issued a press release pursuant to which it announced that Dr. Bernard Kasten, SIGA's Chief Executive Officer, will present at The Wall Street Analyst Forum in New York City on November 30 at 11:40 AM. This conference is held at The Roosevelt Hotel located on 45th Street & Madison Ave. Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at (802) 253-7596, or Dianne Will, Investor Relations for SIGA Technologies, at (518) 398-6222 to request additional information. A live webcast of this presentation will be available via the Company's website at www.siga.com or <http://www.vcall.com/CEPage.asp?ID=89885>. An archived presentation will be available on the Company's website for thirty days. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated in this Item 7.01 by reference.

ITEM 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit No. -----	Description -----
----------------------	----------------------

99.1	Press Release dated November 24, 2004.
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Thomas N. Konatich

Thomas N. Konatich
Chief Financial Officer

Date: November 24, 2004

EXHIBIT INDEX

Exhibit Number	Description
- - - - -	- - - - -
99.1	Press Release dated November 24, 2004

SIGA

Contact:
 Dr. Bernard Kasten
 SIGA Technologies, Inc.
 Chief Executive Officer
 (212) 672-9100

Investor Contact:
 Dianne Will
 Willstar Consultants, Inc.
 (518) 398-6222
 dwill@willstar.net

SIGA Technologies To Present at The Wall Street Analyst Forum in
 New York City on November 30, 2004

New York, NY, November 24, 2004 - SIGA Technologies, Inc. (NASDAQ: SIGA), announced today that Dr. Bernard Kasten, SIGA's Chief Executive Officer, will present at The Wall Street Analyst Forum in New York City on November 30, at 11:40 AM. This conference is held at The Roosevelt Hotel located on 45th Street & Madison Ave.

Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at (802) 253-7596, or Dianne Will, Investor Relations for SIGA Technologies, at (518) 398-6222 to request additional information. A live webcast of this presentation will be available via the Company's website at www.siga.com or <http://www.vcall.com/CEPage.asp?ID=89885>. An archived presentation will be available on the Company's website for thirty days.

About SIGA Technologies, Inc.
 SIGA Technologies is applying bacterial genomics in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA has the potential of becoming a significant force in the discovery of vaccine and pharmaceutical agents to fight emerging pathogens. SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria and emerging pathogens. SIGA's vaccine and drug platforms are based on its pioneering research into the structure, function and processing of bacterial surface proteins. SIGA is leveraging these platforms through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain promised funding for its development projects or other needed funding, and (d) SIGA may not be able to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this

presentation, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2003, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at <http://www.sec.gov>. Interested parties may also obtain those documents free of charge from SIGA. SIGA does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

#